More Bad News For Pozen: Another Delay To Market For Yosprala

 
• By Jessica Merrill

The company received a second “complete response” letter from FDA for Yosprala, its fixed-dose combination of aspirin and omeprazole, due to issues with the undisclosed third-party supplier.

More from Approvals

More from Product Reviews